On this page
On the Wegovy label, “maintenance dose” means something narrow: 2.4 mg weekly, the full dose you stay on once titration (raising your dose step by step) is done. Most people asking about it mean something else. They want to know if a lower dose can hold the weight they’ve already lost, so the choice isn’t “full dose forever” or “stop cold.”
Here’s the short answer. No trial has tested it. The way the drug works makes it believable, and clinicians do it anyway, one patient at a time.
Why not just stop?
Because the stopping trials point one way. In STEP 4 (Rubino et al., JAMA 2021), people switched from brand-name semaglutide (Wegovy) to placebo at week 20 and gained back a lot of weight, while people who stayed on it kept losing. SURMOUNT-4 (Aronne et al., JAMA 2024) ran the same test with brand-name tirzepatide (Zepbound). People who stopped gained back about 14% in the next year, and people who stayed on lost another 5.5%.
That’s just what you’d expect from how the drug works. GLP-1 medicines calm the appetite signals in your brain and slow how fast food leaves your stomach, but only while the drug is in your body. Once it clears, your appetite comes back, and the weight follows.
Stopping outright is still a fair choice, and it has its own plan. We cover it in our guide to stopping a GLP-1.
How thin the lower-dose evidence is
How much randomized trial evidence is there for staying on a lower dose? None. STEP 1 (Wilding et al., NEJM 2021, n=1,961) kept people on brand-name semaglutide (Wegovy) 2.4 mg for 68 weeks, and they lost 14.9% on average, compared with 2.4% on placebo. The stopping trials compared the full dose against no dose at all. No study had people lose weight at 2.4 mg and then step down to 1.0 mg to see if the loss held. Can a lower dose hold on to weight the full dose took off? We don’t know.
What we have is a reasonable guess. The lower doses (0.25, 0.5, 1.0, 1.7 mg) are the same drug acting on the same receptors in your body, and holding a weight steady should take less push than bringing it down. At that point the drug no longer has to create a calorie gap. It just has to keep your appetite from bouncing back. That’s a sensible idea, but sensible ideas fail in trials all the time.
What a step-down looks like in practice
Every case is different, because there’s no trial protocol to copy. The dose ladder is a natural guide: it goes up in steps of about 4 weeks, and a step-down walks back down it.
Your clinician decides each step with you. After a step down, watch two things: your appetite (is the food noise back?) and the scale. If hunger comes back and your weight creeps up, tell your clinician. The dose you just left may have been the right one.
Two things change the decision:
- Why you’re on it. SELECT (Lincoff et al., NEJM 2023, n=17,604) studied adults who already had cardiovascular disease. Brand-name semaglutide (Wegovy) lowered their risk of major heart events by 20% in relative terms, on the trial’s full dose, and nobody has shown the benefit holds at a lower dose. If protecting your heart is part of why you take it, stepping down gives up the benefit with the best evidence behind it.
- What happened on the way up. If your appetite was still loud at 1.0 mg while you were raising the dose, 1.0 mg probably won’t hold you on the way down. How you felt at each dose is useful information.
There’s no set schedule for a step-down. How fast to go, and when to stop, is a plan you and your clinician make together and check at follow-ups. A lower dose may not hold your weight, and that’s worth knowing before you start.
The money math
For most people, this is paid out of pocket either way. By law, regular Medicare Part D can’t cover drugs for weight loss, though a temporary Medicare program covers some brand-name GLP-1s for certain people through 2027. Many employer health plans leave them out too. Zappy is cash-pay, and you can use FSA or HSA funds. Current prices for compounded semaglutide and tirzepatide are on each treatment page. (Compounded means made by LegitScript-verified 503A US pharmacies. Compounded medicines themselves are not FDA-approved.)
So price out both plans. Staying on a maintenance dose means paying every month with no end date, for a plan that rests on how the drug works and on clinical judgment rather than a trial. Stopping costs nothing up front. But you’re very likely to gain back much of the weight within a year, and if you then restart, you pay to climb the dose ladder again, which takes about 16 weeks. One plan costs money. Based on what we know now, the other one usually costs you the result.
Decide it before the refill runs out
If you’re on semaglutide and getting close to a weight you’d be happy to keep, bring up the maintenance question one refill early. A planned step-down with scheduled check-ins works better than improvising when your last pen runs out. At Zappy, a clinician reviews every case within 24 hours, including dose changes. And if you’re still figuring out whether a GLP-1 is right for you at all, start with the quiz.
The trial that would settle this hasn’t been run. It would have people reach their goal on 2.4 mg and then randomly assign them to step down or stay. Until that happens, a lower maintenance dose is what it is today: a judgment call, made one step at a time, with your own appetite telling you how it’s going.
